Issues in solid-organ transplantation in children: translational research from bench to bedside
Lipshultz SE, Chandar JJ, Rusconi PG, Fornoni A, Abitbol CL, Burke GW, Zilleruelo GE, Pham SM, Perez EE, Karnik R, Hunter JA, Dauphin DD, Wilkinson JD. Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics 2014, 69: 55-72. PMID: 24860861, PMCID: PMC3884162, DOI: 10.6061/clinics/2014(sup01)11.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAntibody-mediated rejectionRenal transplantationCardiac transplantationGraft rejectionAcute antibody-mediated rejectionChronic antibody-mediated rejectionCardiac allograft vasculopathyPanel reactive antibodyPediatric renal transplantationPediatric cardiac transplantationCardiac graft rejectionSolid organ transplantationBiomarkers of inflammationCardiac transplant rejectionRole of biomarkersNew diagnostic approachAllograft vasculopathyHeart transplantationKidney transplantationEndomyocardial biopsyABO incompatibilityTransplant rejectionCardiomyocyte injuryAntibody assaysImmune functionAnthracycline-related cardiotoxicity in childhood cancer survivors
Lipshultz SE, Karnik R, Sambatakos P, Franco VI, Ross SW, Miller TL. Anthracycline-related cardiotoxicity in childhood cancer survivors. Current Opinion In Cardiology 2014, 29: 103-112. PMID: 24284979, DOI: 10.1097/hco.0000000000000034.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnthracycline-related cardiotoxicityCardiovascular complicationsAnthracycline treatmentRisk factorsCardioprotective agentGrowth hormone replacement therapyPrevention of cardiotoxicityHormone replacement therapySerious cardiovascular complicationsChildhood cancer survivorsLong-term outcomesUse of biomarkersDosage of anthracyclinesCardiac transplantationCardiac dysfunctionCancer survivorsCardiac injuryClinical manifestationsReplacement therapyEarly recognitionChildhood cancerCardiotoxic effectsΒ-blockersEnzyme inhibitorsCardiotoxicity